Designed for adults 18 and older, SleepioRx complements standard care by delivering cognitive behavioral therapy for insomnia via a prescription device. This 90-day treatment adapts to individual symptoms, offering daily sleep tracking and on-the-spot therapeutic content to assist with sleep.
“The FDA’s clearance of SleepioRx is a landmark milestone for Big Health, providing accessible, guideline-recommended, first-line treatment for insomnia,” Big Health CEO Yael Berman said in the Aug. 8 release. “This clearance, coupled with the new proposed reimbursement codes, will for the first time motivate U.S. healthcare providers to prescribe safe and effective treatment alternatives to traditional medication.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
